Skip to Content Skip to Search

Late-stage pipeline review - Sir Andrew Witty, Dr Moncef Slaoui, and Dr Patrick Vallance

Sir Andrew Witty (CEO), Dr Moncef Slaoui (Chairman of R&D) and Dr Patrick Vallance (President of Pharmaceutical R&D) together with senior R&D leaders hosted a seminar focusing on GSK’s late stage pipeline. The event brought together the progress made in 2012, as Phase III programmes for a significant number of potential new drugs have concluded. It also provided an overview of our progress on our returns driven strategy in R&D and the sustainability of our pipeline.

Back to top